Cargando…
The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients
OBJECTIVE: The association of lipoprotein(a) [Lp(a)] with atherosclerotic cardiovascular disease (ASCVD) risk can be modified by chronic systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a reliable and easily available marker of immune response to various infectious and non-infectio...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328105/ https://www.ncbi.nlm.nih.gov/pubmed/37426518 http://dx.doi.org/10.2147/IJGM.S410840 |
_version_ | 1785069727854362624 |
---|---|
author | Wang, Xiaoyu Chen, Xiaoli Wang, Yanfang Peng, Sheng Pi, Jingjiang Yue, Jinnan Meng, Qingshu Liu, Jie Zheng, Liang Chan, Paul Tomlinson, Brian Liu, Zhongmin Zhang, Yuzhen |
author_facet | Wang, Xiaoyu Chen, Xiaoli Wang, Yanfang Peng, Sheng Pi, Jingjiang Yue, Jinnan Meng, Qingshu Liu, Jie Zheng, Liang Chan, Paul Tomlinson, Brian Liu, Zhongmin Zhang, Yuzhen |
author_sort | Wang, Xiaoyu |
collection | PubMed |
description | OBJECTIVE: The association of lipoprotein(a) [Lp(a)] with atherosclerotic cardiovascular disease (ASCVD) risk can be modified by chronic systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a reliable and easily available marker of immune response to various infectious and non-infectious stimuli. The purpose of this study was to assess the combined effects of Lp(a) and NLR in predicting the ASCVD risk and coronary artery plaque traits. METHODS: This study included 1618 patients who had coronary computed tomography angiography (CTA) with risk assessment of ASCVD. CTA was used to evaluate the traits of coronary atherosclerotic plaques, and the association of ASCVD with Lp(a) and NLR was assessed by multivariate logistic regression models. RESULTS: Plasma Lp(a) and NLR were significantly increased in patients having plaques. High Lp(a) was defined as the plasma Lp(a) level > 75 nmol/L and high NLR as NLR > 1.686. The patients were grouped into four categories according to normal or high NLR and plasma Lp(a) as nLp(a)/NLR-, hLp(a)/NLR-, nLp(a)/NLR+ and hLp(a)/NLR+. The patients in the latter three groups had higher risk of ASCVD compared to the reference group nLp(a)/NLR-, with the highest ASCVD risk in the hLp(a)/NLR+ group (OR = 2.39, 95% CI = 1.49–3.83, P = 0.000). The occurrence of unstable plaques was 29.94% in the hLp(a)/NLR+ group, which was significantly higher than groups nLp(a)/NLR+, hLp(a)/NLR- and nLp(a)/NLR- with 20.83%, 26.54% and 22.58%, respectively, and there was a significantly increased risk of unstable plaque in the hLp(a)/NLR+ group compared to the nLp(a)/NLR- group (OR = 1.67, 95% CI = 1.04–2.68, P = 0.035). The risk of stable plaque was not significantly increased in the hLp(a)/NLR+ group compared to the nLp(a)/NLR- group (OR = 1.73, 95% CI = 0.96–3.10, P = 0.066). CONCLUSION: The concomitant presence of elevated Lp(a) and higher NLR is associated with increased unstable coronary artery plaques in patients with ASCVD. |
format | Online Article Text |
id | pubmed-10328105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-103281052023-07-08 The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients Wang, Xiaoyu Chen, Xiaoli Wang, Yanfang Peng, Sheng Pi, Jingjiang Yue, Jinnan Meng, Qingshu Liu, Jie Zheng, Liang Chan, Paul Tomlinson, Brian Liu, Zhongmin Zhang, Yuzhen Int J Gen Med Original Research OBJECTIVE: The association of lipoprotein(a) [Lp(a)] with atherosclerotic cardiovascular disease (ASCVD) risk can be modified by chronic systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a reliable and easily available marker of immune response to various infectious and non-infectious stimuli. The purpose of this study was to assess the combined effects of Lp(a) and NLR in predicting the ASCVD risk and coronary artery plaque traits. METHODS: This study included 1618 patients who had coronary computed tomography angiography (CTA) with risk assessment of ASCVD. CTA was used to evaluate the traits of coronary atherosclerotic plaques, and the association of ASCVD with Lp(a) and NLR was assessed by multivariate logistic regression models. RESULTS: Plasma Lp(a) and NLR were significantly increased in patients having plaques. High Lp(a) was defined as the plasma Lp(a) level > 75 nmol/L and high NLR as NLR > 1.686. The patients were grouped into four categories according to normal or high NLR and plasma Lp(a) as nLp(a)/NLR-, hLp(a)/NLR-, nLp(a)/NLR+ and hLp(a)/NLR+. The patients in the latter three groups had higher risk of ASCVD compared to the reference group nLp(a)/NLR-, with the highest ASCVD risk in the hLp(a)/NLR+ group (OR = 2.39, 95% CI = 1.49–3.83, P = 0.000). The occurrence of unstable plaques was 29.94% in the hLp(a)/NLR+ group, which was significantly higher than groups nLp(a)/NLR+, hLp(a)/NLR- and nLp(a)/NLR- with 20.83%, 26.54% and 22.58%, respectively, and there was a significantly increased risk of unstable plaque in the hLp(a)/NLR+ group compared to the nLp(a)/NLR- group (OR = 1.67, 95% CI = 1.04–2.68, P = 0.035). The risk of stable plaque was not significantly increased in the hLp(a)/NLR+ group compared to the nLp(a)/NLR- group (OR = 1.73, 95% CI = 0.96–3.10, P = 0.066). CONCLUSION: The concomitant presence of elevated Lp(a) and higher NLR is associated with increased unstable coronary artery plaques in patients with ASCVD. Dove 2023-07-03 /pmc/articles/PMC10328105/ /pubmed/37426518 http://dx.doi.org/10.2147/IJGM.S410840 Text en © 2023 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wang, Xiaoyu Chen, Xiaoli Wang, Yanfang Peng, Sheng Pi, Jingjiang Yue, Jinnan Meng, Qingshu Liu, Jie Zheng, Liang Chan, Paul Tomlinson, Brian Liu, Zhongmin Zhang, Yuzhen The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients |
title | The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients |
title_full | The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients |
title_fullStr | The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients |
title_full_unstemmed | The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients |
title_short | The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients |
title_sort | association of lipoprotein(a) and neutrophil-to-lymphocyte ratio combination with atherosclerotic cardiovascular disease in chinese patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328105/ https://www.ncbi.nlm.nih.gov/pubmed/37426518 http://dx.doi.org/10.2147/IJGM.S410840 |
work_keys_str_mv | AT wangxiaoyu theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT chenxiaoli theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT wangyanfang theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT pengsheng theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT pijingjiang theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT yuejinnan theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT mengqingshu theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT liujie theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT zhengliang theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT chanpaul theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT tomlinsonbrian theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT liuzhongmin theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT zhangyuzhen theassociationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT wangxiaoyu associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT chenxiaoli associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT wangyanfang associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT pengsheng associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT pijingjiang associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT yuejinnan associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT mengqingshu associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT liujie associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT zhengliang associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT chanpaul associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT tomlinsonbrian associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT liuzhongmin associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients AT zhangyuzhen associationoflipoproteinaandneutrophiltolymphocyteratiocombinationwithatheroscleroticcardiovasculardiseaseinchinesepatients |